Oncotelic's Sapu003 Breast Cancer Treatment to Be Presented at 2025 San Antonio Symposium

Oncotelic Therapeutics Inc. (OTCQB: OTLC) announced that Sapu003, an investigational intravenous Deciparticle formulation of everolimus, has been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium scheduled for December 9-12, 2025. The symposium represents one of the most significant annual gatherings of breast cancer researchers and clinicians worldwide, making this acceptance a notable milestone for the developing therapy.

Sapu003 represents a significant advancement in cancer treatment technology as a novel Deciparticle formulation specifically designed to improve bioavailability, reduce toxicity, and enhance tumor penetration in HR⁺/HER2⁻ metastatic breast cancer, renal cell carcinoma (RCC), and neuroendocrine tumors (NET). The treatment was developed by Sapu Nano, a joint venture between Oncotelic Therapeutics and Dragon Oversea, showcasing the growing importance of international partnerships in advancing cancer therapeutics.

The presentation at this prestigious medical conference carries substantial implications for cancer patients and the pharmaceutical industry. Improved bioavailability means patients could potentially receive lower doses while maintaining therapeutic effectiveness, potentially reducing treatment costs and side effects. The reduced toxicity profile addresses one of the major challenges in cancer treatment - managing the severe side effects that often accompany traditional chemotherapy and targeted therapies.

For investors and industry observers, the latest developments regarding Oncotelic Therapeutics are available through the company's newsroom at https://ibn.fm/OTLC. The enhanced tumor penetration capability of Sapu003 could represent a breakthrough in treating solid tumors that have traditionally been difficult to target effectively with conventional drug delivery systems.

The significance of this development extends beyond the immediate clinical applications. As a clinical-stage biopharmaceutical company, Oncotelic's progress with Sapu003 demonstrates the viability of their PDAOAI platform and nanomedicine expertise. The company's approach to addressing high-unmet-need cancers through innovative late-stage therapeutic candidates could establish new standards for cancer treatment development. The full details of the Sapu003 presentation and supporting data can be accessed through the complete press release available at https://ibn.fm/wB4Hl.

This announcement comes at a time when the global oncology therapeutics market continues to expand, with breast cancer treatments representing one of the largest segments. The development of more effective, less toxic treatments like Sapu003 could potentially transform standard care protocols and improve quality of life for cancer patients worldwide. The upcoming presentation will provide the medical community with critical data needed to assess the therapy's potential impact on current treatment paradigms.